These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12728848)

  • 1. Drug cost. States concerned about Fuzeon.
    AIDS Policy Law; 2003 Apr; 18(7):5. PubMed ID: 12728848
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug pricing. High price of Fuzeon, other recent drugs sets tough pricing precedent.
    AIDS Policy Law; 2005 Jul; 20(14):4. PubMed ID: 16108122
    [No Abstract]   [Full Text] [Related]  

  • 3. US FDA approves new class of HIV therapeutics.
    Robertson D
    Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
    [No Abstract]   [Full Text] [Related]  

  • 4. FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank?
    Sharp M; Camp R
    GMHC Treat Issues; 2003 Mar; 17(3):7-8. PubMed ID: 12728858
    [No Abstract]   [Full Text] [Related]  

  • 5. T-20: most expensive AIDS drug ever at $25,000 per year?
    James JS
    AIDS Treat News; 2003 Mar; (389):6-7. PubMed ID: 12712938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-20 (Fuzeon) gets priority review.
    AIDS Treat News; 2002 Oct; (384):4-5. PubMed ID: 12434762
    [No Abstract]   [Full Text] [Related]  

  • 7. Long path to approval. A look back at the road to Fuzeon.
    GMHC Treat Issues; 2003 Mar; 17(3):1-5. PubMed ID: 12728856
    [No Abstract]   [Full Text] [Related]  

  • 8. Enfuvirtide (Fuzeon) for HIV Infection.
    Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA notifications. Genentech issues letter about Fuzeon® co-product.
    AIDS Alert; 2011 Apr; 26(4):47-8. PubMed ID: 21623626
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA news. Price criticized for new anti-HIV drug.
    AIDS Alert; 2003 May; 18(5):67-8. PubMed ID: 12751460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 12. Three new drugs approved by FDA.
    Hoyt G
    Surviv News (Atlanta Ga); 2003; ():13, 20. PubMed ID: 14696579
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-HIV drug updates--three drugs on the near horizon.
    Proj Inf Perspect; 2003 Jan; (35):4-7. PubMed ID: 12647672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ConFuzeon reigns.
    Huff B
    GMHC Treat Issues; 2003 Apr; 17(4):10. PubMed ID: 12751446
    [No Abstract]   [Full Text] [Related]  

  • 15. First fusion inhibitor for advanced HIV.
    Am J Nurs; 2003 Jul; 103(7):64F. PubMed ID: 12877130
    [No Abstract]   [Full Text] [Related]  

  • 16. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV.
    Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA approval: maraviroc.
    Sax PE
    AIDS Clin Care; 2007 Sep; 19(9):75. PubMed ID: 18398993
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 19. Indian company seeks US approval for generic AIDS drugs.
    Nature; 2004 Aug; 430(7001):716. PubMed ID: 15306779
    [No Abstract]   [Full Text] [Related]  

  • 20. Five new drugs enter the homestretch.
    Huff B
    GMHC Treat Issues; 2002 Dec; 16(12):1-4. PubMed ID: 12635598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.